新辅助免疫化学疗法与新辅助化学放射疗法与新辅助化学疗法对切除食道状细胞癌的治疗:一项临床回顾性研究
Jiazhen Chen1, Chuanwang Miao2, Xiaoyue Wang3
1Department of Radiation Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.
BMC cancer
|August 5, 2025
概括
在食道状细胞癌 (ESCC) 中的新辅助免疫化学疗法 (NICT) 与其他新辅助治疗相比,减少了手术并发症和改善了存活率. 对于可切除ESCC患者来说,NICT提供了一个有前途的选择.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 新辅助疗法对于食道状细胞癌 (ESCC) 是至关重要的,增强了局部控制和生存.
- 对可切除ESCC的最佳新辅助剂策略需要持续调查.
研究的目的:
- 为了比较新辅助免疫化学疗法 (NICT),化学辐射疗法 (NCRT) 和化学疗法 (NCT) 在可手术的ESCC患者的疗效和安全性.
- 评估不同新辅助治疗的手术并发症,病理反应和生存结果.
主要方法:
- 从300名可切除ESCC患者的术前临床数据的回顾性分析.
- 患者在2018年1月至2022年8月期间接受了NICT,NCRT或NCT.
- 评估结果包括手术并发症,病理反应和生存率.
主要成果:
- 与NCRT相比,NICT的手术并发症发生率较低 (17.6%与36.3%相比),与NCT (17.6%与22.9%) 的发生率相似.
- 与NCRT和NCT相比,NICT显示出优异的2年无复发存活率 (81.3%) 和整体存活率 (93.4%).
- 完整的病理反应率与NICT比NCRT更低,但高于NCT.
结论:
- 新辅助免疫化学疗法 (NICT) 显著减少了手术并发症,并改善了可切除ESCC的存活率.
- 在ESCC的新辅助治疗中,NICT为化学辐射疗法 (NCRT) 和化疗 (NCT) 提供了令人信服的替代方案.
- 尽管病理缓解率略低,但NICT的生存益处值得考虑.
更多相关视频
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
194
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
377
相关概念视频
01:21Cancer Survival Analysis
455
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
455
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K